WHY DOSE MONITORING IS IMPORTANT WITH CAMZYOS

CAMZYOS is a once-daily oral medication with individualised dosing and titration to optimise treatment benefit while supporting patient safety.1

  • CAMZYOS reduces left ventricular ejection
    fraction (LVEF).1

  • The clinical and echo monitoring is critical
    to optimise the efficacy and safety/tolerability
    of CAMZYOS. Patients should be monitored
    for obstructive HCM symptoms, left
    ventricular outflow tract (LVOT) gradient with Valsalva manoeuvre and LVEF using echos.1
  • If at any visit, the patient’s LVEF is <50%, treatment should be interrupted for 4
    weeks and until LVEF returns to ≥50%.
    Patients on 2.5 mg who temporarily
    interrupted treatment on two consecutive occasions due to LVEF <50% should
    discontinue treatment.1
  • CAMZYOS is metabolised by CYP2C19
    and CYP3A4, and patients may metabolise CAMZYOS at different rates. Terminal half-
    life is 6-9 days in normal metabolisers and
    23 days in poor metabolisers.1

  • Concomitant use of CAMZYOS with certain CYP2C19 or CYP3A4 inhibitors or inducers
    may lead to increased risk of heart failure
    or loss of therapeutic response.1

  • Initiating, modifying or discontinuing
    the dose of certain CYP2C19 or CYP3A4
    inhibitors or inducers may require clinical assessment and dose adjustment
    of CAMZYOS.1

foot note heading